Background: A sepsis care bundle of intravenous vitamin C, thiamine, and hydrocortisone was reported to improve treatment outcomes. The data to support it are uncertain and decision makers are likely to be cautious about adopting it. The objective of this study was to model the opportunity costs in dollars and lives of waiting for better information before adopting the bundle. Methods: A decision tree was built using information from the literature. We modelled the impact of bundle adoption under three scenarios using a simulation in which the bundle was effective as reported in the primary trial, less effective based on other information, and ineffective. The measurements were health services costs, quality-adjusted life years, and transition probabilities. Results: If the bundle proves to be effective under either scenario, it will save billions of dollars and millions of life-years in the United States. This is the opportunity cost of delaying an adoption decision and waiting for better quality evidence. We suggest that hospital decision-makers consider implementing the bundle on a trial basis while monitoring costs and outcomes data even while the evidence base is uncertain. Conclusions: If the decision maker is unwilling to use the best available evidence now, but rather wishes to wait for definitive evidence they are risking incurring large costs for health care systems and for the patients they serve. An explicit analysis of uncertain clinical outcomes is a useful adjunct to guide decision making where there is clinical ambiguity. This approach offers a valid alternative to the default of clinical inactivity when faced with uncertainty.
Introduction
Sepsis arises frequently among patients admitted to hospitals in the US and elsewhere. It is often fatal, accounting for 30% to 50% of inpatient deaths 1 . Those who survive incur large costs from increased risk of organ damage 2 . A recent paper by Marik et al. (2017) described the effectiveness of a treatment bundle made up of intravenous vitamin C, thiamine and hydrocortisone 3 . Because of small sample size, non-randomised design, large observed treatment effects and the simple and low cost characteristics of the bundled intervention, there was scepticism among clinicians, administrators and payers regarding adoption 4-6 . Rapid adoption without good evidence has risks and costs, yet delaying an effective treatment imposes larger costs to patients and the health system. Waiting for conclusive evidence might be a poor and costly strategy and should be balanced against the likely costs of rapid adoption with uncertain and low quality evidence.
The aim of this paper is to estimate the economic consequences of a decision to adopt the Marik sepsis bundle early, under conditions of large uncertainty. This is compared to the alternative, which is to wait 2.5 years; the time period between publication of the first paper in June 2017 3 and the completion of several multi-centre trials of the bundle in late 2019. The trials will ideally reduce the uncertainty in an adoption decision. This paper predicts the cost savings and health benefits of adopting the Marik bundle immediately with uncertain evidence for the entire United States health system, compared to waiting for better quality evidence. Our estimates examine likely changes to costs and health outcomes if the treatment is found to be effective, less effective and ineffective.
Methods
An incremental cost-effectiveness analysis was conducted on the change to costs and Quality-Adjusted Life Years (QALYs) of standard sepsis care compared to the early adoption of the Marik bundle 3 . Values for expected costs and health utilities were taken from the literature, with probabilities of treatment outcomes taken from Marik's paper 3 . The time horizon was 5 years in order to sufficiently measure the long-term outcomes of acute renal failure (ARF), an important and common result of severe septic shock 2 . A decision tree was programmed in TreeAge Pro 2017 R2.1 (Williamstown, MA2017) and prior statistical distributions of costs, outcomes and probabilities used to include uncertainties in the data, see Figure 1 . Patients receiving either modality progress through a chance node to ARF or not. Patients progress through a second chance node, where they either recover or die. Surviving ARF patients progress through a final chance node where they may require chronic renal replacement therapy (RRT), which can take the form of either dialysis or organ transplantation 2 .
Costs
The costs of care include the hospital cost of a sepsis episode, the additional cost of the Marik treatment bundle, the additional cost of an episode of ARF, and the annual ongoing cost of RRT. Hospital costs were taken from a systematic review by Arefian et al. (2017) for a US perspective with a mean of $32,421 and standard deviation of $15,051 per stay 7 . For the Marik bundle, we used an estimate of $528 and a standard deviation of 5% at $26.50 per patient per course. The additional cost of a hospital episode of ARF was taken from Silver et al. (2017) as $11,016 with a standard error of $279.59 8, 9 . The annual cost of RRT for end stage renal disease varies depending on treatment modality, such as dialysis or transplant, and a weighted average of $76,936, with a standard deviation of $15,387 was taken from the 2017 USRDS Annual Data Report 10 .
Health utilities
The health utility score of patients reflects the value of their heath state and is a measure of health related quality of life. It is expressed on a range between zero, the worst health state, and one, the best possible health state 11 . The scores for patients who recover from septic shock depend on whether or not they suffered ARF. Patients who did not suffer ARF still underwent the stress of intensive care unit recovery, and their mean health utility scores and standard deviations were taken from Cuthbertson et al. (2010) at 1, 2.5, and 5 years as 0.666 (0.280), 0.701 (0.281), and 0.677 (0.301), respectively 12 . Survivors of acute kidney problems were found to have a utility of 0.40 with a standard deviation of 0.37 at 60 days. We did not find evidence of improved health utilities over the 5 year period 13 . The health utility of death was valued at 0 11 .
Transition probabilities
The transition probabilities of patients moving through the decision tree were informed by data from Marik's study. This includes the probabilities of survival and ARF, see Table 1 3 . In Marik's study, the Marik bundle's probability of death and ARF were 0.085 and 0.097, with standard errors of 0.041 and 0.043 respectively. These compared to the standard care mortality and ARF probabilities of 0.404 and 0.234, with standard errors of 0.071 and 0.062 respectively. Full transition probabilities are available in Dataset 1.
Modelling additional scenarios
Scenario 1 uses probabilities from the literature for mortality and ARF; costs and utilities were unchanged. The attributable mortality risk and rate of ARF in the general population vary in the literature and are different to those reported in Marik's control cohort. We used the mortality risk associated with These are lower than the rates seen in Marik's observation group. This led to an overall mortality rate of 25.5%, consistent with several studies on septic shock 15,18 .
Scenario 2 represents a worst-case scenario, in which Marik's bundle is ineffective and there is no difference in probabilities between the bundle and standard care. We modelled scenario 2 using the same transition probabilities found in scenario 1 for both arms of the decision tree. As in scenario 1, costs and utilities remained unchanged, though we carried the worst-case QALY outcome to illustrate the unlikely possibility of minor harm.
Probabilistic sensitivity analysis
Probabilistic sensitivity analysis was conducted on the decision tree by taking 1000 random resamples of values from the prior statistical distributions of model parameters. This propagates all uncertainty in the data forward to the results and provides useful information for decision making.
Results
The Scenario 2 is that there is no change to outcomes between Marik's bundle and standard care. The mean cost per patient over 5 years is $37,022USD for standard care and $37,550USD for the Marik bundle, an increase of $528 per patient over a 5 year period. There is no difference in QALYs between treatment alternatives. We were unable to find any evidence of harm to the patient as a result of the bundle. Hydrocortisone and thiamine are already present in routine sepsis care, and the dosage of 6g of vitamin C per day has been shown to be safe unless contraindicated [19] [20] [21] . In this scenario, assuming the intervention is universally adopted, no patients will have been harmed, but healthcare payers and providers would have spent an additional $1.3bn USD over 2.5 years. For the sake of illustration we have carried the worst possible health outcome from scenario 1 to scenario 2. The probabilistic sensitivity analysis shows a negative health outcome arises 2.5% of the time. Outcomes from the scenario analyses are listed in Table 2 below. Data on distributions used in the analysis.
Dataset 1. Sepsis Distributions

Discussion
We found that adopting the Marik bundle has a high likelihood to save billions of dollars and generate millions of extra QALYs under the conditions outlined in Marik's paper and in an alternate scenario that uses other data. Under the ineffective treatment of scenario 2 costs are increased to health services by $0.5bn per year. These results reveal substantial opportunity costs in dollars and lives if we fail to implement and the bundle is ultimately found to be effective, even if the treatment effect is lower than purported by Dr Marik. If the bundle does not work then some costs have been incurred by hospitals for no heath gain. Not adopting the bundle because the evidence for effectiveness is currently uncertain could well be a poor strategy. The worst possible outcome from the base case is that we spend around $5,700 per QALY; given a conventional $50,000/QALY valuation, this gives us a net monetary benefit of $108bn over 2.5 years 22 .
The scenario analysis uses values at which the Marik bundle is less effective, specifically by aligning observation group figures with the literature. The mortality rate of sepsis under standard care was suggested by Marik to be 40.4%. Sepsis mortality has been declining in the US, from 46.9% in the early 1990s to 21.2% in 2014, declining by about 3% per annum and driven by improved organ support systems and protocoled early recognition and treatment 17, 23, 24 . It might be that Marik's study featured unusually sick patients in the control group. Study participants are often unrepresentative of the general population and the intervention group may have been less likely to suffer an adverse outcome 25 . This progress in sepsis care management is complicated by the fact that claims data has shown concurrently increasing sepsis incidence and decreasing mortality, so the literature is conflicted 26, 27 . It is possible that the increased incidence from claims data is due to increased reimbursement received by US hospitals for sepsis compared to other diseases, and patients are being misdiagnosed. An increasing rate of misdiagnosis of patients that do not have sepsis increases the denominator of septic cases while mortality stays the same in the numerator, creating the illusion of declining mortality 17, 27 .
Regarding the mortality of Marik's treatment group, we note the significant improvement in outcomes recommending the use of steroids in adults with septic shock by Annane et al. (2018) 28 . Patients randomised to the steroid group (n = 614) showed a 6% absolute reduction in 90-day all-cause mortality when compared to placebo (n = 627). Therefore, the figures in Marik's patient cohort may have been unusual, but they are plausible.
There is no current body of evidence that suggests this bundle is dangerous. Indeed, the combination of vitamin C and thiamine with steroids would have to cause an attributable death once in every 10 sepsis patients -by a hitherto unimagined and novel mechanism -to negate the modelled benefits of its early adoption.
Limitations
Our study excluded the costs of bundle implementation, including training, labour and the potential for high costs of de-implementing an unsuccessful treatment. These would have increased the cost of bundle implementation, so the incremental cost of the Marik bundle may be understated. We noted that hydrocortisone, as part of the bundle, was found by Venkatesh (2018) to speed up resolution of shock and reduce the need for blood transfusions, so the in-hospital cost-savings for the treatment group may also be understated 21 . We were also unable to quantify the potential QALY gains from reductions in post-sepsis syndrome associated with the Marik bundle, understating the gains in utility from the bundle. There is also considerable uncertainty around the parameter estimates that are available. We did not have access to primary data, including clinical data on costs and transition probabilities for each patient, and were reliant on the literature.
Bundle adoption decision
An average hospital in the US may treat around 230 sepsis patients per year 16 . By implementing the bundle, it will spend an additional $528 per patient, or $121,440 per year. Conservative estimates from the scenario analysis shows cost savings of $2,590 and a gain of 0.46 QALYs per patient. If the treatment was effective for 47 patients out of 230, or 1 in 5, it will have paid for itself in terms of total economic costs. Comparing implementing the sepsis bundle to other hospital-based treatment studies shows that for 230 patients, the bundle costs less than a tenth of a standard phase I clinical trial, which run from $1.4m-$6.5m 29 .
The case for not adopting the Marik bundle has several components. Scientific and empirical evidence is thin, and a single-site Vitamin C trial showing remarkable results only to be proven ineffective after a multi-site RCT is a clinical trope. If the bundle was ineffective, health systems will have added an unnecessary load to clinicians and implementers, which would then have to be de-implemented. Administrators and clinicians may be less likely to adopt novel treatments in the future. Introducing the bundle on the current evidence may also set a bad precedent for novel treatments, eroding the authority of the presiding physician and giving more credence to largely unproven interventions. The proposal in this paper does not replace the need for the clarity provided by good science and empirical research, but these are not always immediately available. We provide an approach to explicitly guide the interim decisions that must be made under these circumstances.
The Marik bundle is a somewhat unusual case relative to most 'miracle' interventions later found to be ineffective. As the analysis shows, it is an extremely cheap treatment with the potential to reduce rates of mortality and kidney damage at no risk to the patient. The delay between publication of the pilot study and results of the large RCT due in 2019 could create substantial opportunity costs in dollars and lives, and while there is not perfect evidence, under the circumstances it might be sufficient for hospitals and health systems to choose whether to conduct their own trials and not only independently verify their results, but also publish their findings and improve the availability of evidence around the treatment bundle.
The implementation decision of the Marik bundle relies upon the willingness of health administrators to use the available evidence to influence policy. We attempted to make the bundle choice as intuitive as possible, using straightforward trade-offs, simple modelling techniques, and a realistic decision process. Merlo et al. (2014) showed that for research to be accessible to decision-makers, it must be contextually relevant, contain little jargon, and put the terms of the implementation decision into terms that specify a trade-off that will be familiar to decisionmakers 30 . If the decision maker is unwilling to use the best available evidence now, but rather wishes to wait for definitive evidence they are risking incurring large costs for health care systems and for the patients they serve.
Conclusion
An explicit analysis of uncertain clinical outcomes is a useful adjunct to guide decision making where there is clinical ambiguity. This approach offers a valid alternative to the default of clinical inactivity when faced with uncertainty. This fascinating paper uses a simple health economics model to argue that delaying the widespread implementation of the Vitamin C protocol as described by Marik and colleagues would lead to the loss of enormous potential savings to the health industry. The argument is well presented, easily followed, and sound, with some exceptions.
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There is likely to be some inaccuracy in the figures presented. The authors state that there are 1.5 million cases of sepsis in the United States yearly (no reference supplied, but data easily available via the CDC). Whilst there may indeed be this number who meet the recently updated definition of sepsis, this large cohort of patients are different to those who have a mortality rate of 40% with standard care. This group, as described in Marik's paper, are a much sicker population. Their number is likely to be significantly fewer than 1.5 million. Whilst it is not known whether Vitamin C may have benefits in a less sick population, it is unlikely that 'early adopters' of this therapy will consider it in those that are not towards the severe end of the sepsis spectrum. Reducing the exposed population in the model from 1.5 million will reduce the proposed savings by a proportional amount.
Similarly, the quoted incidence of requirement for renal replacement therapy is overstated. It is true that the Marik Vitamin C-treated group had an incidence of RRT-requiring AKI of 9.7%. However, the Marik paper does not state that these patients all went on to require ongoing RRT for ESRF (at the authors' quoted cost of $77,000 per year). The majority of patients who require RRT in the setting of sepsis-induced AKI will recover their renal function either completely, or enough that they do not require ongoing dialysis. Again, reducing the stated financial benefits of this aspect of the Vitamin C treatment will reduce the long-term economic attractiveness of the therapy.
Overall however, the authors are correct in their statement that the economic implications of adopting the 'bundle' will be positive. Furthermore, the economic implications should be secondary to the beneficial effects the treatment may have on mortality. Again, this therapy is unlikely to be offered to 1.5 million patients per year, but whatever the number, those who receive it are likely to benefit.
A major strength of the paper is their use of a more pessimistic scenario (scenario 1) than published in the Marik study to demonstrate the robustness of their figures. The Marik-stated improvement in mortality, from 40% to 8%, is likely to not be repeated in larger studies, as it is simply too great to be plausible. Reducing the relative risk reduction such that mortality is reduced from 21% to 8% may be more realistic, and yet the economic figures still add up to considerable savings.
It would perhaps also be useful to see a model where baseline mortality of 40% (ie the very sick cohort It would perhaps also be useful to see a model where baseline mortality of 40% (ie the very sick cohort from Marik) have their mortality reduced to, say, 30% (ie a more plausible magnitude of effect from Vitamin C).
The authors have done well to pick this particular therapy to demonstrate their model. The Vitamin C bundle is unique in recent years, in that it is a cheap and seemingly safe therapy. Their model is unlikely to be able to be used for supporting other therapies that emerge in coming years, given the likelihood that these therapies will come from the pharmaceutical industry and have large price tags attached.
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